Share this article

DermTech has filed a patent for a method of detecting skin cancer, specifically cutaneous T cell lymphoma (CTCL), mycosis fungoides (IVIF), or Sézary syndrome (SS), based on molecular risk factors. The method involves isolating nucleic acids from a skin sample, measuring the expression level of target genes associated with CTCL, and using a software program to evaluate the gene expression signature to determine the presence or progression of CTCL. GlobalData’s report on DermTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights DermTech Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on DermTech, predictive cancer diagnosis models was a key innovation area identified from patents. DermTech's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Method of analyzing gene expression signature for ctcl detection

Source: United States Patent and Trademark Office(USPTO). Credit: DermTech Inc

A recently filed patent (Publication Number: US20230142201A1) describes a method for analyzing a gene expression signature associated with cutaneous T cell lymphoma (CTCL) in a skin sample. The method involves isolating nucleic acids from the skin sample obtained from a subject suspected of having CTCL using an adhesive patch. The patch is applied to a skin region and then removed, retaining the adhered skin sample cells. The expression level of a panel of target genes known to be upregulated or downregulated in CTCL is measured, and a software program or module is used to evaluate the gene expression levels and determine the gene expression signature of the skin sample. Based on this signature, a sample score is provided, indicating the presence or absence and/or progression of CTCL.

The method can be used with mRNA as the nucleic acids and does not require the presence of melanocytes in the skin sample. Multiple adhesive patches can be used to obtain skin sample cells from different regions. The method is applicable to skin lesions and can be used to guide the administration of CTCL treatment, which may include steroids, interferon, chemotherapy, phototherapy, radiation therapy, or a bone marrow transplant. The specific types of CTCL that can be analyzed using this method include mycosis fungoides and Sézary syndrome.

In addition to the method, the patent also describes a kit for determining the presence of CTCL in a skin sample. The kit includes an adhesive patch, a nucleic acid isolation reagent, and a plurality of probes that recognize target genes associated with CTCL.

The panel of target genes used in the method can include genes encoding saposin-like proteins, FYN-binding protein family members, TEC kinase family members, STATs, TRAF3 interacting proteins, CXC chemokine family members, modulators of cell death, antimicrobials, cytokines, DNA-binding proteins, or combinations thereof. At least three target genes are recommended, with specific examples including FYB, GNLY, ITK, STAT5, TRAF3IP3, CXCL10, CXCL8, TNF, IL26, DNM3, and TNFSF11.

The software program or module used to evaluate the gene expression levels can apply various models, such as random forest, boosting, logit, lasso, or combinations thereof. Additionally, the method can involve detecting mutational changes in other target genes and using the software program or module to evaluate these changes in determining the gene expression signature.

Overall, this patent presents a method and kit for analyzing gene expression signatures associated with CTCL in skin samples, providing a potential tool for diagnosing and guiding the treatment of this type of lymphoma.

To know more about GlobalData’s detailed insights on DermTech, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies